Member News
-
East Side Games Group Announces Expansion of Mighty Kingdom Partnership
January 12, 2022 (Source) — East Side Games Group (TSX: EAGR) (OTC: EAGRF) (“ESGG” or the “Company”), Canada’s leading…
-
Voyageur Pharmaceuticals Announces IRR of 137% and NPV of $344 Million from Preliminary Economic Assessment for the Frances Creek Pharmaceutical Barium Project
January 11, 2022 (Source) — Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV: VM) is pleased to announce…
-
Hemostemix to Combine ACP-01 with Dr. James Shapiro’s Islet Cells to Treat Type 1 Diabetes
January 11, 2022 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Carbon Streaming Welcomes Alice Schroeder to Board of Directors
Board Addition Enhances U.S. Governance as Part of U.S. Listing Strategy January 11, 2022 (Source) — Carbon Streaming…
-
Neo Lithium Receives Catamarca Government Approval of its Environmental Impact Assessment for the Construction and Operation of its 3Q Project
January 11, 2022 (Source) — Neo Lithium Corp. (“Neo Lithium” or the “Company”) (TSXV: NLC) (OTCQX: NTTHF) (FSE: NE2) is…
-
Commencement of Second Phase IXOS Test Work at the Fenix Gold Project
January 11, 2022 (Source) — Rio2 Limited (TSXV: RIO) (OTCQX: RIOFF) (BVL: RIO) (“Rio2”) and Sixth Wave Innovations Inc. (CSE: SIXW) (OTCQB: SIXWF)…
-
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events…
-
Zentek Announces First Direct Orders Under Its Medical Device Establishment License
January 11, 2022 (Source) — Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization…
